Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open Label Extension Study of Pegunigalsidase Alfa (PRX-102) in Fabry Disease
2018-001148-67Phase 3Unknown
- Sponsor
- Protalix BioTherapeutics
- Start
- May 2018
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, PEGylated Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pegunigalsidase alfa in Fabry disease (FD), sponsored by Protalix BioTherapeutics. Primary endpoint: Safety endpoints. Status: unknown.
02
Drugs
pegunigalsidase alfa
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on 2018-001148-67.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001148-67.